Blood nitrates content in patients with systemic lupus erythematosus and antiphospholipid syndrome


Cite item

Full Text

Abstract

Aim. To elucidate clinical implications of nitrates (NOJ concentration as an indicator of nitric oxide (NO) level in blood serum of patients with systemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (PAPS).
Material and methods. Blood serum concentration of N03 was measured by high-performance liquid chromatography in a total of 41 patients with SLE (n = 17), PAPS (n = 14) and secondary APS (n - 9). Sera from 10 healthy subjects (donors) served as control. N03 concentration > 40 mcmol/l was stated high. SLE activity was assessed by V. A. Nasonova 's scale and SLEDAI index (SLEDAI > 9 indicated SLE exacerbation). Patients with PAPS were divided into two groups depending on clinical symptoms: 7 patients with significant thrombosis or history of more than two thrombotic complications (group 1); 7patients with the history of two or less thromboses (group 2). Results. The mean serum nitrate concentration in the SLE group was 43.59 mcmol/l (range 17.06113.22). The nitrate level of the sAPS + SLE group was 49.81 ± 27.54 and did not significantly differ from APS (33.67 ± 14.70). By univariate standard analyses, serum nitrate concentration was significantly higher in patients with high disease activity (57.31 ± 25.12 vs. 25.62 ± 6.96, Mann-Whitney test, p < 0.01). The Spearman correlation coefficient of nitrate level with SLEDAI was 0.8 (p < 0.001). Conclusion. A nitrate level is increased in patients with active SLE and in APS patients with severe thrombotic complication.

References

  1. Clancy R. M., Amin A. R., Abramson S. B. The role of nitric oxide in inflammation and immunity. Arthr. and Rheum. 1998; 41 (7): 1141-1151.
  2. Farrell A. J., Blake D. R. Nitric oxide. Ann. Rheum. Dis. 1996; 55: 7-20.
  3. Tan E. M., Cohen A. S., Fries J. F. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthr. and Rheum. 1982; 25: 1271-1277.
  4. Bombardier C., Gladman D. D., Urowits M. B. et al. The development and validation of the SLE disease activity index (SLE-DAI). Arthr. and Rheum. 1992; 35: 630-640.
  5. Wilson W. A., Gharavi A. E., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthr. and Rheum. 1999; 42: 1309-1311.
  6. Кобылянский А. Г., Кузнецова Т. В., Соболева Г. Н. и лр. Определение оксида азота в сыворотке и плазме крови человека. Метод высокоэффективной жидкостной хроматографии. Биомед. химия 2003; 6.
  7. Александрова Е. И., Насонов Е. Л., Ковалев В. Ю. Количественный иммуноферментный метод определения антител к кардиолипину в сыворотке крови. Клин, ревматол. 1995; 4: 35-39.
  8. Но С. Y., Wong С. К., Li E. К. et al. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42 (1): 117-122.
  9. Wanchu A., Khullar M., Deodhar S. D. et al. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol. Int. 1998; 18 (2): 41-43.
  10. Belmont H. M., Levartovsky D., Goel A. et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthr. and Rheum. 1997; 40 (10): 1810-1816.
  11. Wigand R., Meyer J., Busse R., Becker M. Increased serum NG-hydroxy-L-arginine in patients with rheumatoid arthritis and systemic lupus erythematosus as an index of an increased nitric oxide synthase activity. Ann. Rheum. Dis. 1997; 56 (5): 330-332.
  12. Wong С. К, Но С. Y., Li E. К. et al. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2002; 130 (2): 345-351.
  13. Wang J. S., Tseng H. H., Shih D. F. et al. Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 1997; 77 (4): 404-411.
  14. Reilty С. M., Family L. W., Viti D. et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int. 2002; 61 (3): 839- 846.
  15. Jonsson С. A., Carbten H. Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell. Immunol. 2002; 216 (1-2): 93-101.
  16. Yu С. С., Yang С. W., Wu M. S. et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J. Lab. Clin. Med. 2001; 138 (1): 69-77.
  17. Lui S. L., Tsang A., Wong D. et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002; 11 (7): 411-418.
  18. Huang F. P., Feng G. J., Lindop G. et al. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL inverted question markMP-lpr inverted question marklpr mice. J. Exp. Med. 1996; 183 (4): 1447-1459.
  19. At Suwaidi J., Hamasaki S., Higano S. T. et al. Long-term follow-up of patients with mild coronary artery disease and endothelial disfunction. Circulation 2000; 101: 948-954.
  20. Lima D. S. N., Sato E. I., Lima V. С. et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol. 2002; 29: 292-297.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies